• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - August 19, 2021 Category: International Medicine & Public Health Source Type: research

Cancers, Vol. 13, Pages 2254: Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.
Source: Cancers - May 8, 2021 Category: Cancer & Oncology Authors: Matteo Franchi Roberta Tritto Luigi Tarantini Alessandro Navazio Giovanni Corrao Tags: Article Source Type: research

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - April 8, 2021 Category: International Medicine & Public Health Source Type: research

Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial
CONCLUSIONS: Ramipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ARCADIA, NCT00985322 and European Union Drug Regulating Authorities Clinical Trials Database number 2008-003529-17.PMID:33782036 | DOI:10.2215/CJN.12940820
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 30, 2021 Category: Urology & Nephrology Authors: Piero Ruggenenti Manuel Alfredo Podest à Matias Trillini Annalisa Perna Tobia Peracchi Nadia Rubis Davide Villa Davide Martinetti Monica Cortinovis Patrizia Ondei Carmela Giuseppina Condemi Carlo Maria Guastoni Agnese Meterangelis Antonio Granata Emanuel Source Type: research

Healthy People Shouldn ’ t Take Daily Aspirin To Prevent Heart Disease, Review Finds
(CNN) — Still taking a daily aspirin to ward off heart attacks? You might want to think again, according to a new review. Aspirin is still one of the most commonly used medications in the world, even though it’s no longer recommended as a preventative by many health authorities. There is no evidence that low-dose aspirin — less than 325 milligrams a day — should be taken by most adults in good cardiovascular health, according to a new review of existing research that published Wednesday in the British Journal of Clinical Pharmacology. The review, which focused on the risks and benefits of low-dose daily asp...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 3, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News aspirin CNN Source Type: news

Abnormal ankle-brachial index (ABI) predicts primary and secondary cardiovascular risk and cancer mortality.
CONCLUSIONS: The co-existence of abnormal ABI and a history of CV events identifies subjects at higher risk, who call for a more aggressive approach. Abnormal ABI is also a predictor of cancer mortality. PMID: 32151490 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - March 5, 2020 Category: Internal Medicine Authors: Visonà A, De Paoli A, Fedeli U, Tonello D, Zalunardo B, Zanatta N, Martini R, Pesavento R, Cuppini S, Prior M, Benazzi S, Cimminiello C, Avossa F Tags: Eur J Intern Med Source Type: research

Extra-virgin olive oil for potential prevention of Alzheimer disease.
Authors: Román GC, Jackson RE, Reis J, Román AN, Toledo JB, Toledo E Abstract Observational epidemiological studies provide valuable information regarding naturally occurring protective factors observed in populations with very low prevalences of vascular disease. Between 1935 and 1965, the Italian-American inhabitants of Roseto (Pennsylvania, USA) observed a traditional Italian diet and maintained half the mortality rates from myocardial infarction compared with neighboring cities. In the Seven Countries Study, during 40years (1960-2000) Crete maintained the lowest overall mortality rates and coronary heart dise...
Source: Revue Neurologique - September 16, 2019 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Should You Take Aspirin Every Day? Here ’s What the Science Says
Aspirin is best known as an over-the-counter painkiller. But acetylsalicylic acid, as it’s called chemically, has many other health benefits, as well as side effects, in the body that have only become clear in recent years. Here’s what the latest science says about the health benefits and side effects of aspirin, as well as which conditions it may treat and those it doesn’t appear to improve. (If you are taking aspirin for any reason other than for periodic pain relief, it’s best to consult with your doctor to confirm whether the benefits outweigh the risks in your particular case.) How aspirin affe...
Source: TIME: Health - November 8, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthytime Source Type: news

Urine Arsenic and Arsenic Metabolites in U.S. Adults and Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction: A Cross-Sectional Study
Conclusion: In a cross-sectional study of U.S. adults, we observed some positive associations of uAs and toenail As concentrations with biomarkers potentially relevant to CVD pathogenesis and inflammation, and evidence of a higher capacity to metabolize inorganic As was negatively associated with a marker of oxidative stress. https://doi.org/10.1289/EHP2062 Received: 14 April 2017 Revised: 13 November 2017 Accepted: 15 November 2017 Published: 15 December 2017 Address correspondence to S.F. Farzan, 2001 N. Soto St., Los Angeles, CA, 90032. Telephone: (323)-442-5101; Email: sffarzan@usc.edu Supplemental Material is ava...
Source: EHP Research - December 16, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Weight Loss in Italy?
One of the women I work with wanted to know about the new diet drug called Belviq. The FDA is always approving a new “miracle” weight-loss pill, only to recall it a few years later. To date, at least 34 diet drugs have been taken off the market. Diet pills cause all kinds of problems — heart attack, stroke and psychiatric disorders. And Belviq isn’t any different. Some of its side effects include suicidal thoughts, a racing heartbeat, hallucinations and more… The European Union banned Belviq. The reason? It causes cancer in animals.  And here’s the real irony… Clinical trials found ...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-yea...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research